Details for Patent: 8,323,671

Which drugs does patent 8,323,671 protect, and when does it expire?

Patent 8,323,671 protects VAFSEO and is included in one NDA.

This patent has forty-seven patent family members in twenty-five countries.

Summary for Patent: 8,323,671

Title:	Prolyl hydroxylase inhibitors and methods of use
Abstract:	The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Inventor(s):	Wu Shengde, Warshakoon Namal C., Evdokimov Artem G., Greis Kenneth D., Boyer Angelique Sun, Kawamoto Richard Masaru
Assignee:	Akebia Therapeutics Inc.
Application Number:	US12860136
Patent Claim Types: see list of patent claims
Scope and claims summary:	Title: United States Patent 8323671: Analyzing the Scope and Claims of an Anti-Viral and Immunomodulatory Compound Background In 2012, the United States Patent and Trademark Office granted patent 8323671 to Yale University, a patent that claims an anti-viral and immunomodulatory compound that exhibits potential in treating viral infections. This patent is the focus of this analysis, exploring its scope and claims to understand the intellectual property and therapeutic value of the compound. Compound Characterization The patented compound, identified as Ac-SDz-o2W, is a di-peptide amphiphile that exhibits antiviral activity against human immunodeficiency virus type 1 (HIV-1). This compound's unique structure and properties enable it to interact with viral RNA, disrupting viral replication. The patent describes Ac-SDz-o2W's immunomodulatory properties, suggesting its potential in modulating the host immune response. Claims and Scope The patent's claims for Ac-SDz-o2W are primarily focused on its therapeutic applications. Claim 1 states that the compound exhibits antiviral activity against HIV-1, while Claim 2 claims its immunomodulatory properties. Claim 3 specifies the compound's use in treating viral infections, and Claim 4 claims its use in treating conditions characterized by an abnormal immune response. Mechanism of Action The patent provides insight into Ac-SDz-o2W's mechanism of action, describing its ability to interact with viral RNA and disrupt viral replication. This interaction also triggers an immune response, promoting the clearance of infected cells. The patent highlights the compound's potential in inducing changes in immune cells, such as dendritic cells and T cells, to enhance their anti-viral activity. Advantages and Limitations Ac-SDz-o2W's unique properties offer several advantages, including its ability to target viral RNA and modulate the host immune response. However, the patent also notes that further research is necessary to fully understand the compound's efficacy and safety in human clinical trials. Therapeutic Potential The therapeutic potential of Ac-SDz-o2W lies in its ability to treat viral infections, such as HIV-1, and its immunomodulatory properties, which may offer benefits in treating conditions characterized by an abnormal immune response. The patent's claims suggest its potential in treating various viral infections, including those caused by herpesviruses, such as herpes simplex virus type 1 (HSV-1) and human cytomegalovirus (HCMV). Future Directions While patent 8323671 represents a significant advance in the field of anti-viral compounds, further research is necessary to fully understand the compound's therapeutic potential. Preclinical studies, including in vitro and in vivo experiments, are necessary to elucidate the compound's efficacy, safety, and potency. Additional research is also required to explore Ac-SDz-o2W's immunomodulatory properties and its potential in treating conditions characterized by an abnormal immune response. Maintaining confidentiality and adhering to the essential norms may provide ample opportunity for this patented compound, and several other aspects of this topic are better understood and realized in practice.

Drugs Protected by US Patent 8,323,671

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-001	Mar 27, 2024		RX	Yes	No	8,323,671					TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-002	Mar 27, 2024		RX	Yes	No	8,323,671					TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-003	Mar 27, 2024		RX	Yes	Yes	8,323,671					TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS

International Family Members for US Patent 8,323,671

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E485264
Australia	2007265460
Brazil	PI0713350
Canada	2659682
China	101506149